Highlights and Quick Summary
Current EV/EBITDA of AbbVie Inc. is 10.53 (as of December 30, 2019)
- EV/EBITDA for the quarter ending March 30, 2020 was 8.87 (a -15.79% decrease compared to previous quarter)
- Year-over-year quarterly EV/EBITDA decreased by -43.14%
- Annual EV/EBITDA for 2019 was 10.53 (a -50.78% decrease from previous year)
- Annual EV/EBITDA for 2018 was 21.39 (a 27.98% increase from previous year)
- Annual EV/EBITDA for 2017 was 16.72 (a 33.69% increase from previous year)
Visit stockrow.com/ABBV
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EV/EBITDA of AbbVie Inc.
Most recent EV/EBITDAof ABBV including historical data for past 10 years.Interactive Chart of EV/EBITDA of AbbVie Inc.
AbbVie Inc. EV/EBITDA for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2020 | 8.87 | – | – | – | – |
| 2019 | 10.53 | 16.39 | 15.59 | 18.22 | 10.53 |
| 2018 | 21.39 | 14.25 | 15.23 | 14.93 | 21.39 |
| 2017 | 16.72 | 14.96 | 13.09 | 12.52 | 16.72 |
| 2016 | 12.5 | 12.89 | 13.43 | 12.74 | 12.5 |
| 2015 | 14.28 | 19.52 | 27.34 | 22.42 | 14.28 |
| 2014 | 26.44 | 15.7 | 14.3 | 13.27 | 26.44 |
| 2013 | 13.53 | 10.97 | 10.05 | 10.12 | 13.53 |
| 2012 | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 |
| 2011 | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 |
| 2010 | – | – | – | – | 9.05 |
| 2009 | – | – | – | – | 9.05 |
Business Profile of AbbVie Inc.
Sector: Medical
Industry: Drugs
AbbVie Inc., a research-based biopharmaceutical company, develops and markets pharmaceutical products in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a biologic therapy administered as an injection for autoimmune and intestinal diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the treatment of patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; and Janssen Biotech, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.